Do analysts recommend ACXP or VIRI?

Acurx Pharmaceuticals currently has a consensus price target of $31.00, suggesting a potential upside of 1,939.47%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ACXP or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is ACXP or VIRI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Virios Therapeutics N/A -130.33% -115.00%

Is EVAX or ACXP more profitable?

Evaxion A/S's return on equity of -73.56% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Acurx Pharmaceuticals N/A -153.92% -101.69%

Is BRNS or ACXP more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% Acurx Pharmaceuticals N/A -153.92% -101.69%

Acurx Pharmaceuticals (ACXP) Competitors

$1.52 -0.03 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

ACXP vs. VIRI, EVAX, BRNS, CPHI, and MRKR

Should you buy Acurx Pharmaceuticals stock or one of its competitors? MarketBeat compares Acurx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acurx Pharmaceuticals include Virios Therapeutics (VIRI), Evaxion A/S (EVAX), Barinthus Biotherapeutics (BRNS), China Pharma (CPHI), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.

How does Acurx Pharmaceuticals compare to Virios Therapeutics?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

In the previous week, Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
Virios Therapeutics	Neutral

Acurx Pharmaceuticals has a beta of -2.05, meaning that its share price is 305% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

Acurx Pharmaceuticals currently has a consensus price target of $31.00, suggesting a potential upside of 1,939.47%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Virios Therapeutics' return on equity of -130.33% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

Acurx Pharmaceuticals beats Virios Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Evaxion A/S has higher revenue and earnings than Acurx Pharmaceuticals. Evaxion A/S is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.34	-$7.71M	-$1.47	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evaxion A/S's return on equity of -73.56% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

In the previous week, Evaxion A/S had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 2 mentions for Evaxion A/S and 0 mentions for Acurx Pharmaceuticals. Evaxion A/S's average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Evaxion A/S	Neutral
Acurx Pharmaceuticals	Neutral

Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.05, meaning that its stock price is 305% less volatile than the broader market.

Evaxion A/S currently has a consensus price target of $11.00, indicating a potential upside of 264.24%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,939.47%. Given Acurx Pharmaceuticals' higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Evaxion A/S beats Acurx Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.73	-$66.43M	-$1.29	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Barinthus Biotherapeutics currently has a consensus price target of $4.00, indicating a potential upside of 531.91%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,939.47%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Barinthus Biotherapeutics has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.05, indicating that its stock price is 305% less volatile than the broader market.

Barinthus Biotherapeutics' return on equity of -63.83% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

In the previous week, Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Acurx Pharmaceuticals	Neutral

Summary

Barinthus Biotherapeutics beats Acurx Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to China Pharma?

Acurx Pharmaceuticals (NASDAQ:ACXP) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, China Pharma had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 3 mentions for China Pharma and 0 mentions for Acurx Pharmaceuticals. China Pharma's average media sentiment score of 0.54 beat Acurx Pharmaceuticals' score of 0.00 indicating that China Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
China Pharma	Positive

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Acurx Pharmaceuticals has a beta of -2.05, suggesting that its share price is 305% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Acurx Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 1,939.47%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Acurx Pharmaceuticals is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

China Pharma has higher revenue and earnings than Acurx Pharmaceuticals. China Pharma is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
China Pharma	$3.99M	82.23	-$3.08M	-$0.55	N/A

Acurx Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

China Pharma beats Acurx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Marker Therapeutics?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Acurx Pharmaceuticals has higher earnings, but lower revenue than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Marker Therapeutics	$3.55M	5.96	-$12.16M	-$0.61	N/A

Acurx Pharmaceuticals has a beta of -2.05, meaning that its stock price is 305% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Acurx Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

In the previous week, Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
Marker Therapeutics	Neutral

Acurx Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 1,939.47%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 687.40%. Given Acurx Pharmaceuticals' higher probable upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Marker Therapeutics beats Acurx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACXP vs. The Competition

Export

Metric	Acurx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.54M	$3.66B	$6.82B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.38	20.80	27.00	24.20
Price / Sales	N/A	322.97	519.38	94.43
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.73	8.17	10.67	6.26
Net Income	-$7.97M	$23.81M	$3.60B	$331.76M
7 Day Performance	-7.88%	-1.12%	-0.32%	-1.10%
1 Month Performance	-1.30%	2.64%	1.88%	-1.26%
1 Year Performance	-82.16%	45.50%	25.50%	18.84%

Acurx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACXP Acurx Pharmaceuticals	2.336 of 5 stars	$1.52 -1.9%	$31.00 +1,939.5%	-82.8%	$6.54M	N/A	N/A	3
VIRI Virios Therapeutics	N/A	$1.38 -2.8%	N/A	-71.4%	$26.58M	N/A	N/A	5
EVAX Evaxion A/S	2.5723 of 5 stars	$3.03 +0.3%	$11.00 +263.0%	+11.8%	$25.19M	$7.53M	N/A	60	Gap Up
BRNS Barinthus Biotherapeutics	1.7536 of 5 stars	$0.61 +0.5%	$4.00 +552.5%	-58.2%	$24.92M	$14.97M	N/A	107
CPHI China Pharma	N/A	$0.61 -1.6%	N/A	-48.4%	$24.91M	$3.99M	N/A	250	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACXP) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. VIRI, EVAX, BRNS, CPHI, and MRKR

How does Acurx Pharmaceuticals compare to Virios Therapeutics?

Summary

How does Acurx Pharmaceuticals compare to Evaxion A/S?

Summary

How does Acurx Pharmaceuticals compare to Barinthus Biotherapeutics?

Summary

How does Acurx Pharmaceuticals compare to China Pharma?

Summary

How does Acurx Pharmaceuticals compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. VIRI, EVAX, BRNS, CPHI, and MRKR

How does Acurx Pharmaceuticals compare to Virios Therapeutics?

Does the media prefer ACXP or VIRI?

Which has more volatility and risk, ACXP or VIRI?

Do analysts recommend ACXP or VIRI?

Which has higher valuation & earnings, ACXP or VIRI?

Do institutionals & insiders have more ownership in ACXP or VIRI?

Is ACXP or VIRI more profitable?

Summary

How does Acurx Pharmaceuticals compare to Evaxion A/S?

Which has higher valuation & earnings, EVAX or ACXP?

Do institutionals & insiders believe in EVAX or ACXP?

Is EVAX or ACXP more profitable?

Does the media favor EVAX or ACXP?

Which has more risk & volatility, EVAX or ACXP?

Do analysts prefer EVAX or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Barinthus Biotherapeutics?

Which has better valuation & earnings, BRNS or ACXP?

Do analysts rate BRNS or ACXP?

Do institutionals and insiders hold more shares of BRNS or ACXP?

Which has more risk and volatility, BRNS or ACXP?

Is BRNS or ACXP more profitable?

Does the media prefer BRNS or ACXP?

Summary

How does Acurx Pharmaceuticals compare to China Pharma?

Does the media refer more to ACXP or CPHI?

Do insiders and institutionals hold more shares of ACXP or CPHI?

Which has more risk and volatility, ACXP or CPHI?

Do analysts recommend ACXP or CPHI?

Which has higher earnings & valuation, ACXP or CPHI?

Is ACXP or CPHI more profitable?

Summary

How does Acurx Pharmaceuticals compare to Marker Therapeutics?

Which has preferable earnings & valuation, ACXP or MRKR?

Which has more volatility and risk, ACXP or MRKR?

Is ACXP or MRKR more profitable?

Does the media refer more to ACXP or MRKR?

Do analysts rate ACXP or MRKR?

Do insiders and institutionals hold more shares of ACXP or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools